Peter Lawson
Stock Analyst at Barclays
(1.46)
# 3,547
Out of 5,008 analysts
100
Total ratings
42.53%
Success rate
-11.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Initiates: Overweight | $385 | $341.62 | +12.70% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $26.92 | +48.59% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $20.16 | +24.01% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $4.65 | -35.48% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $39.63 | +0.93% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.72 | +74.42% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.39 | +43.88% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.14 | +231.89% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $5.77 | +73.31% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $2.18 | +83.49% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $12.03 | -50.12% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $9.43 | +16.65% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $9.30 | +72.04% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $8.00 | +87.50% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $14.03 | -0.21% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.85 | +62.60% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.97 | +52.28% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.29 | +210.08% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $46.57 | +28.84% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $5.83 | +191.60% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $16.45 | +100.61% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $34.22 | +92.87% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $9.83 | +215.36% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $7.29 | +78.33% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.44 | +247.22% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $3.33 | +5.11% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $96.68 | +277.53% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $40.87 | +12.55% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $58.00 | +675.86% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $3.93 | +1,045.04% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $70.62 | -36.28% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Sep 18, 2025
Initiates: Overweight
Price Target: $385
Current: $341.62
Upside: +12.70%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $26.92
Upside: +48.59%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $20.16
Upside: +24.01%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $4.65
Upside: -35.48%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $39.63
Upside: +0.93%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.72
Upside: +74.42%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.39
Upside: +43.88%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.14
Upside: +231.89%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $5.77
Upside: +73.31%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.18
Upside: +83.49%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $12.03
Upside: -50.12%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $9.43
Upside: +16.65%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $9.30
Upside: +72.04%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $8.00
Upside: +87.50%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $14.03
Upside: -0.21%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.85
Upside: +62.60%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.97
Upside: +52.28%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.29
Upside: +210.08%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $46.57
Upside: +28.84%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $5.83
Upside: +191.60%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $16.45
Upside: +100.61%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $34.22
Upside: +92.87%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $9.83
Upside: +215.36%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $7.29
Upside: +78.33%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.44
Upside: +247.22%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $3.33
Upside: +5.11%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $96.68
Upside: +277.53%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $40.87
Upside: +12.55%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $58.00
Upside: +675.86%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $3.93
Upside: +1,045.04%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $70.62
Upside: -36.28%